April 16th 2024
Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
VITALIZE Trial Explores Maveropepimut-S/Pembrolizumab in Relapsed/Refractory DLBCL
September 15th 2022In an interview with Targeted Oncology, Matthew Matasar, MD, discusses background information on the ongoing VITALIZE trial of maveropepimut-S in patients with diffuse large B-cell lymphoma.
Read More
FDA Lifts Partial Clinical Hold on TakeAim Lymphoma Study of Emavusertib/Ibrutinib
August 19th 2022The TakeAim Lymphoma study will continue to evaluate emavusertib with or without ibrutinib in patients with various types of lymphoma after a 4 1/2-month partial clinical hold placed by the FDA.
Read More
FDA Accepts sBLA for Polatuzumab Vedotin Combination in Previously Untreated DLBCL
August 16th 2022By April 2023, the FDA plans have a decision on the approval application for polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone as an option for treatment-naïve diffuse large B-cell lymphoma.
Read More
Zandelisib on Intermittent Dosing Schedule is Safe in R/R B-Cell Malignancies
August 2nd 2022Findings from a phase 1 study concluded zandelisib given to patients with relapsed/refractory B-cell malignancies at 60 mg once daily in an intermittent dosing schedule reflected in a positive safety profile.
Read More
Novel Anti-CD19 CAR T-Cell Therapy Shows Efficacy in Multiple BCL Subtypes
July 30th 2022Manali Kamdar, MD, MBBS, discusses the efficacy and tolerability of a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell lymphoma.
Watch
FDA Grants Fast Track and Rare Pediatric Disease Designations for WU-CART-007 in T-ALL/LBL
July 20th 2022The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Read More